SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001636282-24-000058
Filing Date
2024-08-08
Accepted
2024-08-07 18:53:03
Documents
13
Period of Report
2024-08-07
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K syre-20240807.htm   iXBRL 8-K/A 27173
  Complete submission text file 0001636282-24-000058.txt   163475

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20240807.xsd EX-101.SCH 1896
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20240807_lab.xml EX-101.LAB 24584
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20240807_pre.xml EX-101.PRE 14307
15 EXTRACTED XBRL INSTANCE DOCUMENT syre-20240807_htm.xml XML 3867
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37722 | Film No.: 241185458
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)